Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
- Status
- COMPLETED
- Phase
- PHASE3
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
FPA150 in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2